Abstract Phosphodiesterase 4 (PDE4) belongs to a family of enzymes which catalyzes the
breakdown of 3, 5′-adenosine cyclic monophosphate (cAMP) and is ubiquitously …

Phosphodiesterase-4 (PDE4), mainly present in immune cells, epithelial cells, and brain
cells, manifests as an intracellular non-receptor enzyme that modulates inflammation and …

Phosphodiesterase 4 (PDE4) is a major cyclic AMP-hydrolyzing enzyme in inflammatory and
immunomodulatory cells. The wide range of inflammatory mechanisms under control by …

PDE4D) in mammals. Each PDE4 gene plays a special, nonredundant role in the control of
cell function even though the four subfamilies share the highly conserved catalytic domain …

Phosphodiesterase (PDE) 4 inhibitors have been in development as a novel anti-
inflammatory therapy for more than 20 years, with asthma and chronic obstructive pulmonary …

Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the
treatment of inflammation-based diseases. Several scientific advancements, by both …

Phosphodiesterase (PDE) enzymes are responsible for the inactiviation of cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Phosphodiesterase …

Phosphodiesterase enzymes are responsible for the inactivation of cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Phosphodiesterase …

Preclinical and clinical studies of phosphodiesterase 4 inhibitors have shown that these
agents may find utility in a wide range of inflammatory disorders, including asthma, chronic …

Chronic respiratory diseases affect millions of people every day. According to the World
Health Organization estimates,~ 235 million people suffer from asthma,~ 64 million suffer …